LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Innovation, Investment, and Excellence for Healthcare Biotechnology: Achieving a competitive environment in Europe | EuropaBio Healthcare BioForum, October 2022

23/11/2022
PRESS RELEASE

Brussels, 23 November 2022

EuropaBio hosted its inaugural Healthcare BioForum on October 5, 2022. The roundtable brought together representatives from SMEs, large companies, DGs GROW, Santé and RTD, European Parliament and Member States to discuss links between innovation, investment, and excellence in European healthcare biotechnology. It had the aim to develop dialogue and momentum towards future thriving and competitive Europe through biotechnology innovation.

‘’The Healthcare BioForum was an outstanding opportunity to bring together our community and EU policymakers to  discuss how we can support European healthcare biotechnology sector. Our companies are working very hard to provide with excellent treatment European patients and we need to design the right environment for innovation to flourish. Only then the sector will thrive well, making Europe a leader of healthcare biotechnology in the world.’’, said Dr Claire Skentelbery, Director General of EuropaBio.

Open discussions revealed a common goal to make Europe a leader in healthcare biotechnology, starting with reinforcing dialogue and collaboration between industry and public actors, both at EU and national levels.

Key outcomes from the Healthcare BioForum

  • Europe needs a regulatory system fit for the 21st Century: efficient, flexible, and future proof
  • The EU’s legislative framework should ensure stability and predictability to attract investments
  • Europe’s scientific excellence can be translated into therapeutic innovation by supporting the biotechnology ecosystem
  • Europe should utilise the right tools and resources to ensure a competitive environment in the region
  • The EU innovation ecosystem should be fostered: From academia to startups, to established companies alike

EuropaBio’s inaugural Healthcare BioForum came at a critical time for Europe’s development towards a global centre of excellence, with benefits for patients and economies alike. It demonstrated that stakeholders have a shared vision for what Europe can, and should achieve. Innovators, policy makers, and facilitators can each bring their own expertise, perspective, and role. EuropaBio will help deliver the vision into reality across stakeholders for Europe, and the Healthcare BioForum establishes a long-term platform for open and forward-looking discussion. 

Read the full event report with recommendations HERE.

Innovation, Investment, and Excellence for Healthcare Biotechnology: Achieving a competitive environment in Europe | EuropaBio Healthcare BioForum, October 2022


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.